ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VERV Verve Therapeutics Inc

5.191
0.091 (1.78%)
After Hours
Last Updated: 23:51:28
Delayed by 15 minutes
Share Name Share Symbol Market Type
Verve Therapeutics Inc NASDAQ:VERV NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.091 1.78% 5.191 5.12 5.16 5.16 4.93 5.07 1,593,896 23:51:28

Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03/05/2024 9:01pm

GlobeNewswire Inc.


Verve Therapeutics (NASDAQ:VERV)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more Verve Therapeutics Charts.

Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).

The employees received stock options to purchase an aggregate of 64,200 shares of the company’s common stock and an aggregate of 56,100 restricted stock units (RSUs). The options have an exercise price of $6.01 per share, which is equal to the closing price of the company’s common stock on the date of grant. Each option has a 10-year term and will vest over a period of four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remainder vesting in equal monthly installments over the following three years, subject to each such employee’s continued service with the company on each such vesting date. The RSUs will vest in equal annual installments on the first four anniversaries of July 1, 2024, subject to each such employee’s continued service with the company on each such vesting date.

About Verve Therapeutics Verve Therapeutics, Inc. (Nasdaq: VERV) is a clinical-stage genetic medicines company pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company’s lead programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of atherosclerotic cardiovascular disease (ASCVD). VERVE-101 and VERVE-102 are designed to permanently turn off the PCSK9 gene in the liver and are being developed initially for heterozygous familial hypercholesterolemia (HeFH) and ultimately to treat patients with established ASCVD who continue to be impacted by high LDL-C levels. VERVE-201 is designed to permanently turn off the ANGPTL3 gene in the liver and is initially being developed for homozygous familial hypercholesterolemia (HoFH) and for refractory hypercholesterolemia where patients still have high LDL-C despite treatment with maximally-tolerated standard of care therapies. For more information, please visit www.VerveTx.com.

Investor ContactJen RobinsonVerve Therapeutics, Inc.jrobinson@vervetx.com 

Media ContactAshlea Kosikowski1ABashlea@1abmedia.com 

1 Year Verve Therapeutics Chart

1 Year Verve Therapeutics Chart

1 Month Verve Therapeutics Chart

1 Month Verve Therapeutics Chart

Your Recent History

Delayed Upgrade Clock